Share

January 01, 2019; 92 (1) Views & Reviews

Misdiagnosis of multiple sclerosis

Impact of the 2017 McDonald criteria on clinical practice

Andrew J. Solomon, Robert T. Naismith, Anne H. Cross
First published October 31, 2018, DOI: https://doi.org/10.1212/WNL.0000000000006583
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1572

Share

Article Information

vol. 92 no. 1 26-33
DOI: 
https://doi.org/10.1212/WNL.0000000000006583
PubMed: 
30381369
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received February 19, 2018
  • Accepted in final form July 30, 2018
  • First Published October 31, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Andrew J. Solomon, MD,
    2. Robert T. Naismith, MD and
    3. Anne H. Cross, MD
  1. Andrew J. Solomon, MD,
    2. Scientific Advisory Boards:

    1. (1) Genentech (2) EMD Serono

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Biogen

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Robert T. Naismith, MD and
    3. Scientific Advisory Boards:

    1. 1) Alkermes

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Acorda Therapeutics, speaker honoraria and travel (commercial) 2) Alkermes, consulting and travel (commercial) 3) Biogen IDEC, speaker honoraria and travel (commercial) 4) Genentech, speaker honoraria and travel (commercial) 5) Genzyme Corporation, speaker honoraria and travel (commercial) 6) EMD Serono, consulting honoraria and travel (commercial) 7) Novartis, consulting honoraria and travel (commercial)

    Editorial Boards:

    1. Journal Watch 2010-present, Associate Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. 1) Acorda Therapeutics (commercial) 2) Genzyme Corporation (commercial) 3) Genentech (commercial) 4) Novartis (commercial)

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society National Institutes of Health

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Anne H. Cross, MD
    4. Scientific Advisory Boards:

    1. (1) Roche: member scientific advisory board 2010-2016 (2) Genentech: member of scientific advisory board 2015-2017; (3) Biogen: consulting; (4) EMD-Serono: consulting; (5) Genzyme/Sanofi: consulting; (6) Novartis: consulting; (7) Teva: attendance at advisory board. Non-Profit: (1) Race to Erase MS: reviewing grants, presence at review meetings; (2) National MS Society: speaking; (3) Consortium of MS Centers: participation in Board of Director meetings, talks at meetings

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) gave talk for EMD-Serono in Madrid 2016; (2) spoke at AbbVie meeting, Chicago 2016

    Editorial Boards:

    1. (1) Brain Pathology,Editorial Board, 2008-ongoing - no compensation (2) Editorial Board, Journal of Neuroimmunology, Editorial Board, 1996- ongoing - no compensation (3) 2013 -2016 Associate Editor of Annals Clinical Translational Neurology (I stepped down from this job at end of 2016)

    Patents:

    1. U.S. patent #15060-630 ?Methods for simultaneous multi-angular relaxometry of tissue using magnetic resonance imaging

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Biogen, ad hoc consultant, 2005-2018, (2) Sanofi- Aventis/ Genzyme, ad hoc consultant 2010 -2018 (3) Novartis, ad hoc consultant 2013- 2017; (4) Bayer, ad hoc consultant, 2016, (5) Gerson Lehrman Group Austin Tx, consultant 2009-2018, (6)Guidepoint Global, LLC, New York, New York,consultant, (7) EMD Serono- ad hoc consultant 2012-2018, (8) AbbVie - ad hoc consultant 2016; (9) Genentech - ad hoc consultant 2011-2018, (10) Teva, (11) At Point of Care - writer and commentator on CME programs - ongoing

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Projects in Knowledge, Livingston NJ 07039- fee for writing (2)Prime Education, Inc, fee for giving CME talk - 2016 & 2017; (3) honoraria for reviewing grants and serving on Scientific Advisory Board for Race To ERASE MS 2016-2018 (this is also disclosed in Section #1 above; (4) honoraria for reviewing grants for the Conrad N. Hilton Foundation 2017; (5) Board of Governors Member, Consortium of MS Centers 2016 ongoing; (6) WebMD, honoraria for filming and speaking on topics related to MS 216-2018; (7)PeerView CME: talk at symposium at 2018 annual meeting of CMSC

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Roche site PI for study of ocrelizumab in primary progressive MS (ORATORIO- now in open-label extension called OLE), (2) back-up investigator on a study at our site of ocrelizumab for RRMS (OPERA), began in 2011 and are now in open-label extension, (3) ROche - site PI of OBOE - open-label study intended to better understand mechanism of action of drug, (4) Teva Neuroscience - site PI in study of Vitamin D added at low versus high dose to glatiramer acetate. Study is funded by the National MS Society USA, but Teva is contributing free-of-charge Copaxone to study participants. Ongoing. (5) Biogen - back up site PI for study of opicinumab (anti-LINGO1)

    Research Support, Government Entities:

    1. (1)National Institutes of Health NINDS 2PO1 NS059560- 01

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Barnes-Jewish Hospital Foundation, PI, 2005-2018 (2) Conrad N Hilton Foundation 2014-2019

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurological Sciences (A.J.S.), Larner College of Medicine at The University of Vermont, University Health Center, Burlington; and Department of Neurology (R.T.N., A.H.C.), Washington University in St. Louis, MO.
  1. Correspondence
    Dr. Solomon andrew.solomon{at}uvm.edu
View Full Text

Article usage

Article usage: October 2018 to February 2023

AbstractFullPdfSource
Oct 20182903Highwire
Nov 201815260147Highwire
Dec 2018947102112Highwire
Jan 2019933138115Highwire
Feb 20195326061Highwire
Mar 20197804335Highwire
Apr 20194694047Highwire
May 20194582946Highwire
Jun 20193663562Highwire
Jul 20193293561Highwire
Aug 20193051547Highwire
Sep 20193221630Highwire
Oct 20193232250Highwire
Nov 20193202763Highwire
Dec 20192992552Highwire
Jan 20202501847Highwire
Feb 20202061059Highwire
Mar 2020173626Highwire
Apr 2020178827Highwire
May 2020118517Highwire
Jun 20201261119Highwire
Jul 2020106511Highwire
Aug 2020129418Highwire
Sep 20201411128Highwire
Oct 20201781116Highwire
Nov 20202461123Highwire
Dec 2020159420Highwire
Jan 20212031322Highwire
Feb 202118048Highwire
Mar 20211921018Highwire
Apr 2021184514Highwire
May 2021176411Highwire
Jun 2021138311Highwire
Jul 2021177310Highwire
Aug 2021132212Highwire
Sep 2021219713Highwire
Oct 20212631319Highwire
Nov 2021210715Highwire
Dec 20211661312Highwire
Jan 2022187712Highwire
Feb 202218677Highwire
Mar 20222881322Highwire
Apr 2022257715Highwire
May 2022285919Highwire
Jun 2022173107Highwire
Jul 2022240816Highwire
Aug 202220178Highwire
Sep 2022214108Highwire
Oct 20222561218Highwire
Nov 2022326109Highwire
Dec 202223458Highwire
Jan 2023226129Highwire
Feb 2023203187Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles